1. Sloan B, Scheinfeld N. The use and safety of doxycycline hyclate and other second-generation tetracyclines. Expert opinion on drug safety 2008 Sep;7(5):571-7.
2. Mroczkowsky TF, Mena L, Nsuami M, Martin DH. A randomized comparisonof azithromycin and doxycycline for the treatment of Mycoplasma genitalium (MG) positive urethritis. 16th Biennial Meeting of the International Society of Sexually Transmitted Disease (ISSTDR), Amsterdam, The Netherlands 2005;304-305.
3. Wikstrom A, Jensen JS. Mycoplasma genitalium: a common cause of persistent urethritis among men treated with doxycycline. Sex Transm Infect 2006; 82(4):276-279.
4. Mena LA, Mroczkowski TF, Nsuami M, et al. A randomized comparison of azithromycin and doxycycline for the treatment of Mycoplasma genitalium-positive urethritis in men. Clin Infect Dis 2009;48:1649-54.
5. Guschin A, Ryzhikh P, Rumyantseva T, Gomberg M, Unemo M. Treatment efficacy, treatment failures and selection of macrolide resistance in patients with high load of Mycoplasma genitalium during treatment of male urethritis with josamycin. BMC Infect Dis. 2015 Feb 3; 15:40. (http://www.ncbi.nlm.nih.gov/pubmed/25645440)
6. Andreeva IV, Kozlov SN, Korolev SV, Belikov AN, Grinev AV, Evstaf"ev VV, Kirpicheva NN, Serdiutskaia MV, Stetsiuk OU, Fokin AA, Khrianin AA. Diagnostic and treatment patterns in management of male patients with nongonococcal urethritis: results of Russian multicentral cross-sectional study. Antibiot Khimioter. 2012;57(5-6):32-40. (http://www.ncbi.nlm.nih.gov/pubmed/25645440)
7. Guo X., Ye Z., Deng R. Male urogenital tract mycoplasma infection and drug-resistance evolution. Josamycin - das bessere Makrolid? Zhonghua Nan Ke Xue 10(2) (2004) 122-124. (http://www.ncbi.nlm.nih.gov/pubmed/25645440)
8. Jernberg E, Moghaddam A, Moi H. Azithromycin and moxifloxacin for Microbiological cure of Mycoplasma genitalium infection: an open study. International journal of STD & AIDS 2008 Oct;19(10):676-9. (http://www.ncbi.nlm.nih.gov/pubmed/25645440)
9. Ross JD, Cronje HS, Paszkowski T, et al. Moxifloxacin versus ofloxacin plus metronidazole in uncomplicated pelvic inflammatory disease: results of a multicentre, double blind, randomised trial. Sex Transm Infect 2006;82:446-51. (http://www.ncbi.nlm.nih.gov/pubmed/25645440)
10. MMWR Recommendations and Reports / Vol. 64 / No. 3 June 5, 2015/. Sexually Transmitted Diseases Treatment Guidelines, 2015. (http://www.ncbi.nlm.nih.gov/pubmed/25645440)
11. Czeizel AE, Rockenbauer M, Olsen J, S0rensen HT. (http://www.ncbi.nlm.nih.gov/pubmed/25645440)A case-control teratological study of spiramycin, roxithromycin, oleandomycin and josamycin. Acta Obstet Gynecol Scand. 2000 Mar;79(3):234-7. (http://www.ncbi.nlm.nih.gov/pubmed/10716307)
12. Czeizel A.E., Rockenbauer M., Olsen J., et al. A case-control teratological study of spiramycin, roxithromycin, oleandomycin and josamycin. Acta Obstet. Gynecol. Scand., 2000, 79, 234-237. (http://www.ncbi.nlm.nih.gov/pubmed/10716307)
13. Клинические рекомендации по ведению больных инфекциями, передаваемыми половым путем, и урогенитальными инфекциями (РОДВК) Москва 2012 (http://www.ncbi.nlm.nih.gov/pubmed/10716307)
14. Кубанова А.А., Рахматулина М.Р. Урогенитальные инфекционные заболевания, вызванные генитальными микоплазмами. Клинические рекомендации. Вестник дерматологии и венерологии. - 2009. - № 3. - С.78-84. (http://www.ncbi.nlm.nih.gov/pubmed/10716307)
15. Рахматулина М.Р. Урогенитальные заболевания, вызванные генитальными микоплазмами (Mycoplasma genitalium, Ureaplasma spp., Mycoplasma hominis) Consilium medicum. -2012. - № 2. - С.22-25. (http://www.ncbi.nlm.nih.gov/pubmed/10716307)
16. Рахматулина М.Р., Касаткина И.С. Современные представления о роли генитальных микоплазм в развитии патологических процессов урогенитальной системы, методах их диагностики и лечения у детей. Вестник дерматологии и венерологии. - 2011. -№ 1 - С. 15-23. (http://www.ncbi.nlm.nih.gov/pubmed/10716307)